• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Waters Corporation Appoints Heather Knight to Board of Directors

    8/14/24 4:15:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $WAT alert in real time by email

    MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International.

    Waters Corporation appointed Heather Knight to its Board of Directors. She currently serves as Executive Vice President and Group President, Medical Products & Therapies at Baxter International.

    Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries.

    "Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for driving growth and innovation," said Dr. Flemming Ornskov, Chair of the Board. "Her experience enriches the diverse skills and backgrounds of our Board members, which is instrumental in our oversight of the strategy and in enhancing shareholder value."

    "We are thrilled to welcome Heather to our Board of Directors," said Dr. Udit Batra, President and CEO, Waters Corporation. "Her commitment to operational excellence coupled with her global experience driving commercial execution and portfolio innovation across the MedTech industry will be complementary to our Board. I look forward to collaborating with her as we advance our growth strategy."

    "It's an honor to join the Waters Board of Directors at such an exciting time," commented Heather Knight, Executive Vice President and Group President of Medical Products and Therapies at Baxter International. "I've long admired the company and look forward to contributing to its success."

    Ms. Knight currently serves as the Executive Vice President and Group President of Medical Products and Therapies at Baxter International. She brings nearly three decades of global business and commercial leadership experience in the pharmaceutical and medical device industries, and a proven track record of driving strong execution, business transformation, and portfolio innovation. She holds a B.S. in Biology from the University of Buffalo.

    About Waters Corporation (www.waters.com)

    Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. With approximately 7,500 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries.

    Contact:

    Kevin Kempskie

    Senior Director Public Relations

    Waters Corporation

    [email protected]

    +1.508.478.2000

    Waters Corporation (PRNewsfoto/Waters Corporation)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/waters-corporation-appoints-heather-knight-to-board-of-directors-302222613.html

    SOURCE Waters Corporation

    Get the next $WAT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WAT

    DatePrice TargetRatingAnalyst
    3/31/2025$460.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/26/2025$396.00 → $407.00Neutral → Outperform
    Robert W. Baird
    2/13/2025$450.00Sector Perform → Sector Outperform
    Scotiabank
    2/10/2025$360.00 → $415.00Underweight → Equal Weight
    Barclays
    1/10/2025$430.00Mkt Perform → Outperform
    Bernstein
    12/23/2024Sector Perform
    Scotiabank
    10/8/2024$355.00 → $415.00Hold → Buy
    Jefferies
    8/28/2024$380.00Overweight
    Wells Fargo
    More analyst ratings

    $WAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP & Chief Financial Officer Chaubal Amol covered exercise/tax liability with 239 shares, decreasing direct ownership by 4% to 5,224 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      5/14/25 5:22:52 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SVP TA Instruments Division Bennett Jianqing covered exercise/tax liability with 303 shares, decreasing direct ownership by 6% to 4,916 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      4/8/25 5:43:17 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Jiang Wei was granted 53 shares, increasing direct ownership by 2% to 2,410 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      4/2/25 5:12:56 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Fearon Richard H bought $332,900 worth of shares (1,000 units at $332.90), increasing direct ownership by 153% to 1,653 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      5/29/24 11:23:35 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $WAT
    SEC Filings

    See more
    • Waters upgraded by KeyBanc Capital Markets with a new price target

      KeyBanc Capital Markets upgraded Waters from Sector Weight to Overweight and set a new price target of $460.00

      3/31/25 7:57:55 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded Waters from Neutral to Outperform and set a new price target of $407.00 from $396.00 previously

      3/26/25 7:47:54 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters upgraded by Scotiabank with a new price target

      Scotiabank upgraded Waters from Sector Perform to Sector Outperform and set a new price target of $450.00

      2/13/25 8:14:37 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form S-8 filed by Waters Corporation

      S-8 - WATERS CORP /DE/ (0001000697) (Filer)

      6/13/25 4:15:59 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SD filed by Waters Corporation

      SD - WATERS CORP /DE/ (0001000697) (Filer)

      5/30/25 4:30:42 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - WATERS CORP /DE/ (0001000697) (Filer)

      5/29/25 4:15:21 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Waters Enhances Alliance iS HPLC System Software, Setting a New Standard for End-to-End Traceability and Data Integrity

      News Summary Industry-first smart HPLC system to provide authenticated user access verification on onboard touchscreen for superior security.Integration of Alliance™ iS HPLC System with Empower™ Software ensures user actions are identifiable and auditable.Minimizes common user errors by up to 40% and enhances audit readiness by providing end-to-end traceability and data integrity.BRUGES, Belgium and MILFORD, Mass., June 17, 2025 /PRNewswire/ -- 54th International Symposium on High-Performance Liquid Phase Separations and Related Techniques - Waters Corporation (NYSE:WAT) today announced the release of the Alliance iS HPLC System Software version 2.0, a significant advancement that delivers c

      6/17/25 10:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer

      News Summary Up to six-fold increase in performance robustness with StepWave™ XR Ion Guide versus Xevo TQ Absolute.1Uses up to 50% less power and gas, and occupies up to 50% less bench space than other products in its class.2Takes the industry-leading sensitivity of Xevo TQ Absolute to new heights, including for PFAS detection and pharma quantitation applications.BALTIMORE and MILFORD, Mass., June 2, 2025 /PRNewswire/ -- 73rd ASMS Conference on Mass Spectrometry and Allied Topics – Waters Corporation (NYSE:WAT) today announced the launch of the Xevo™ TQ Absolute XR Mass Spectrometer, the Company's most sensitive, robust, and reliable benchtop tandem quadrupole. Notably, the product exceeds t

      6/2/25 8:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Introduces BioResolve Protein A Affinity Columns to Accelerate Antibody Titer Measurement, Enhancing Process Agility and Batch Quality

      News Summary Enables measurements up to 2 days earlier for antibody titers for both clone selection and bioprocess monitoring.1Provides up to 7x improvements in sensitivity with novel high efficiency particles.2Delivers 2x more attribute information with simplified multi-attribute workflows.3MILFORD, Mass., May 28, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the launch of the BioResolve™ Protein A Affinity Columns with MaxPeak™ Premier Technology, providing precise titer measurements. This launch marks the first set of affinity chromatography columns that Waters has brought to market, in a groundbreaking move as the Company continues to release new products that solve

      5/28/25 8:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials